Home>>Signaling Pathways>> DNA Damage/DNA Repair>> DNA/RNA Synthesis>>Daptomycin

Daptomycin (Synonyms: LY146032)

Catalog No.GC10214

Daptomycin is a lipopeptide antibiotic with rapid bactericidal activity against Gram-positive bacteria.

Products are for research use only. Not for human use. We do not sell to patients.

Daptomycin Chemical Structure

Cas No.: 103060-53-3

Size Price Stock Qty
10mg
$24.00
In stock
25mg
$46.00
In stock
50mg
$77.00
In stock
100mg
$139.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Protocol Chemical Properties Product Documents Related Products

Daptomycin is a lipopeptide antibiotic with rapid bactericidal activity against Gram-positive bacteria [1]. Daptomycin has in vitro activity against enterococci, staphylococci, streptococci, corynebacteria, and stationary-phase persistent bacteria Borrelia burgdorferi [2]. The antibacterial mechanism of daptomycin is different from that of most antibiotics. It uses acylglycerol phosphate to insert into the cell membrane and agglomerate, change the curvature of the cell membrane and perforate it, thereby triggering cell depolarization and leading to cell necrosis [3].

In vitro, Daptomycin(5μg/ml) reduces Staphylococcus aureus cell viability by >99% and membrane potential by >90% within 30 minutes[4]. Daptomycin (100 μg/ml) treated high-density exponentially growing Staphylococcus aureus ATCC 29213 cells for 60 minutes and had a very rapid bactericidal effect, reducing the number of bacteria by 3 logs[5].

In vivo, Daptomycin (20 mg/kg; i.p.) significantly improved the survival rate and reduced the number of viable bacteria and the level of neutrophil chemotactic factor KC in the peritoneal fluid 6h after treatment of peritonitis mice inoculated with enterococci.[6]. Daptomycin (60 mg/kg; s.c.) has moderate efficacy in the treatment of Staphylococcus aureus osteomyelitis in Sprague-Dawley CD rats [7].

References:
[1]Steenbergen J N , Jeff A , Thorne G M ,et al.Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections[J].Journal of Antimicrobial Chemotherapy2005(3):283-8.
[2] Feng J, Weitner M, Shi W, et al. Eradication of Biofilm-Like Microcolony Structures of Borrelia burgdorferi by Daunomycin and Daptomycin but not Mitomycin C in Combination with Doxycycline and Cefuroxime[J].Frontiers in Microbiology. 2016, 7: 62.
[3] Pogliano J, Pogliano N, Silverman JA. Daptomycin-mediated reorganization of membrane architecture causes mislocalization of essential cell division proteins. Journal of Bacteriology[J].September 2012, 194 (17): 4494–504.
[4] Silverman, Jared A, Perlmutter, et al. Correlation of Daptomycin Bactericidal Activity and Membrane Depolarization in Staphylococcus aureus[J].Antimicrob Agents Chemother. 2003 Aug;47(8):2538-44.
[5] Mascio C T M , Alder J D , Silverman J A. Bactericidal action of daptomycin against stationary-phase and nondividing Staphylococcus aureus cells[J]. Antimicrobial Agents and Chemotherapy, 2007, 51(12): 4255-4260.
[6]Kajihara T1, Nakamura S2, Iwanaga N3, et al. Comparative efficacies of daptomycin, vancomycin, and linezolid in experimental enterococcal peritonitis. J Infect Chemother. 2017 Jul;23(7):498-501.
[7]Poeppl W , Tobudic S , Lingscheid T ,et al. Daptomycin, Fosfomycin, or Both for Treatment of Methicillin-Resistant Staphylococcus aureus Osteomyelitis in an Experimental Rat Model[J].Antimicrobial Agents and Chemotherapy, 2011, 55(11):4999-5003.

Reviews

Review for Daptomycin

Average Rating: 5 ★★★★★ (Based on Reviews and 29 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Daptomycin

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.